Prostate-specific antigen (PSA) has long been a cornerstone in monitoring prostate cancer progression [21], considering the limitations of conventional imaging (e.g., CT and bone scintigraphy), particularly in assessing sclerotic bone metastases [22]. The gene discussed is KLK3; the disease is prostate cancer.